Genmab A/S (GMAB) vs Zoetis (ZTS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Genmab A/S (GMAB) has outperformed Zoetis (ZTS) over the past year, gaining 10.1% versus a loss of 49.1%. Over five years, GMAB leads with a -18.9% price change compared with -63.9% for ZTS. Zoetis is the larger company by market cap ($30.72 billion vs $22.52 billion), about 1.4 times the size, while Genmab A/S is growing revenue faster (+19.2% vs +2.3%).
On valuation, Zoetis trades at a lower forward P/E (11.4x vs 24.0x for Genmab A/S). Zoetis pays a dividend yielding 2.77%, while Genmab A/S does not currently pay one. Zoetis converts more of its revenue into profit, with a net margin of 28.2% versus 25.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GMAB | ZTS |
|---|---|---|
| Share price | $36.62 | $74.35 |
| Market cap | $22.52B | $30.72B |
| 1-day change | +1.58% | +1.74% |
| YTD return | +17.05% | -41.92% |
| 1-year return | +10.11% | -49.07% |
| 5-year return | -18.86% | -63.86% |
| P/E ratio (TTM) | 28.83 | 12.23 |
| Forward P/E | 24.01 | 11.36 |
| EPS (TTM) | $1.27 | $6.08 |
| Dividend yield | 0.00% | 2.77% |
| Annual dividend | $0.00 | $2.06 |
| Revenue (latest FY) | $3.72B | $9.47B |
| Revenue growth (YoY) | +19.19% | +2.28% |
| Net income (latest FY) | $963.00M | $2.67B |
| Gross margin | 93.60% | 71.84% |
| Operating margin | 28.63% | — |
| Net margin | 25.89% | 28.23% |
| 52-week high | $40.17 | $148.30 |
| 52-week low | $23.62 | $68.77 |
| Distance from 52-week high | -8.84% | -49.87% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +18.02% | +29.12% |
| Average volume | 2.83M | 5.46M |
| Shares outstanding | 614.90M | 413.22M |
| Employees | 3,119 | 14,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GMAB has outperformed ZTS by 59.2 percentage points over the past year.
- Genmab A/S trades at a higher earnings multiple (28.8x vs 12.2x trailing P/E).
- Zoetis offers a meaningfully higher dividend yield (2.77% vs 0.00%).
- Genmab A/S grew revenue faster in its latest fiscal year (+19.19% vs +2.28%).
About Genmab A/S
GMAB stock →Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
Health Care · Biotechnology: Pharmaceutical Preparations · 3,119 employees
About Zoetis
ZTS stock →Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 14,500 employees
GMAB vs ZTS FAQ
Which is bigger, Genmab A/S or Zoetis?
Zoetis (ZTS) is larger, with a market capitalization of $30.72B compared with $22.52B for Genmab A/S (GMAB).
Which stock has performed better over the past year, GMAB or ZTS?
GMAB returned +10.11% over the past 12 months, compared with -49.07% for ZTS (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, GMAB or ZTS?
ZTS has the lower trailing P/E at 12.2, versus 28.8 for GMAB. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Genmab A/S or Zoetis?
Zoetis pays a dividend yielding 2.77%, while Genmab A/S does not currently pay a regular dividend.
Are Genmab A/S and Zoetis in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.